Updating results

19 results for ibd

Sort: Relevance | Date

PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)

Advice on PredictSure-IBD for inflammatory bowel disease prognosis to aid local decision making

Medtech innovation briefing Published March 2019

RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

Advice on the use of RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (IBD) to aid local decision-making

Medtech innovation briefing Published June 2017

Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

Advice on the use of point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease

Medtech innovation briefing Published December 2017

NaviCam for diagnosing gastrointestinal tract conditions (MIB104)

Advice on the use of NaviCam for diagnosing gastrointestinal (GI) tract and small bowel conditions to aid local decision-making

Medtech innovation briefing Published May 2017

Biosimilar medicines (KTT15)

infliximab: a successful managed switch programme in people with inflammatory bowel disease discusses the outcomes of a managed...

Key therapeutic topic Published February 2016 Last updated February 2018

Clostridium difficile infection: fidaxomicin (ESNM1)

Summary of the evidence on fidaxomicin for treating Clostridium difficile (C. diff/C. difficile) infection to inform local NHS planning and decision-making

Evidence summary Published July 2012

Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

Summary of the evidence on budesonide multimatrix (Cortiment) for treating ulcerative colitis (UC) to inform local NHS planning and decision-making

Evidence summary Published June 2015

eXroid for internal haemorrhoids (MIB201)

Advice on the use of eXroid, using direct current electrotherapy to blood vessels of internal haemorrhoid to shrink haemorrhoids, to aid local decision making

Medtech innovation briefing Published December 2019

Bile acid malabsorption: colesevelam (ESUOM22)

Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

Evidence summary Published October 2013

Pouchitis: rifaximin (ESUOM30)

Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

Evidence summary Published March 2014

Endo-SPONGE for colorectal anastomotic leakage (MIB188)

Advice on the use of Endo-SPONGE for colorectal anastomotic leakage to aid local decision making

Medtech innovation briefing Published August 2019

Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

Evidence summary Published March 2015

Secca System for faecal incontinence (MIB66)

Advice on the use of the Secca system for treating faecal incontinence to aid local decision-making

Medtech innovation briefing Published May 2016

Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published January 2013

Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published March 2013

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published July 2015

Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

Summary of the evidence on bezlotoxumab for preventing the recurrence of Clostridium difficile (C difficile) infection

Evidence summary Published June 2017

Chronic anal fissure: botulinum toxin type A injection (ESUOM14)

Summary of the evidence on botulinum toxin type A injection for treating chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published June 2013

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017